Examiner Cite _

Remove

Remove

Pages,Columns,Lines where

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

1	Application Number		10593526				
	Filing Date		2007-07-24				
	First Named Inventor	Jean-	Luc Soulard				
	Art Unit		2472				
	Examiner Name Ashill Attorney Docket Number		S. Farahmand				
			PF040046				

Name of Patentee or Applicant

Initial*	No	Patent Number	Code ¹	Issue Date	of cited Document	Figures Appear					
	1										
If you wish to add additional U.S. Patent citation information please click the Add button. Add											
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove					
Examiner Initial*	Examiner Cite No Publication Number Code* Date Name of Patentee or Applicant Relevant Passages or Relevant Figures Appear Figures Appear										
1											
If you wie	If you wish to add additional LLS. Dublished Application situation information places alick the Add button. Add										

U.S. PATENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS
	1	10-210019	JP	A	1998-08-07	Mitsubishi Electric Corporation	English Translation	×
	2	11-177653	JP	A	1999-07-02	NEC Corp.	English Translation	×
	3	2001-028537	JP	A	2001-01-30	Victor Company of Japan, Ltd.	English Translation	×

FOREIGN PATENT DOCUMENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10593526			
Filing Date		2007-07-24			
First Named Inventor Jean-		Luc Soulard			
Art Unit		2472			
Examiner Name Ashil		S. Farahmand			
Attorney Docket Numb	er	PF040046			

4	2001-177401	JP	A	2001-06-29	Mitsubishi Electric Corporation	English Translation	×
5	2002-281077	JP	A	2002-09-27	Hitachi, Ltd.	English Translation	×

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS

Remove

		Holling and an artist and a secondarion		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), itile of the article (when appropriate), itile of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Тŝ	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button Add

				EXAMINER S	IGNA	TURE					
Examiner Signature							Date Considered	Т			
	-		 -			-		-	_	 	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Petent Documents at invent_BETQ_GD(x or MPEP 6016A. 2 Enter office that issued the occument, by the hor-lefter office (WIPO) Standard ST3.) For Lapraence parter for counters, the ancidation of the parent of the register or precedes the sent annumber of the patient document.

**And of document by the appropriate symbols as andicated on the document under WIPO Standard ST1.6 if possible, 2 Applicant is to place a check mark here if Empirical registers received from a sent of the counter of the patient of

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10593526			
Filing Date		2007-07-24			
First Named Inventor Jean-		Luc Soulard			
Art Unit		2472			
Examiner Name	Ashil	S. Farahmand			
Attorney Docket Numb	er	PF040046			

CERTIFICATION STATEMENT

Diagra con	37	CFR .	1 97	and	1 02	to make	the	annonnista	selection(s)	,

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Patricia A. Verlangieri/	Date (YYYY-MM-DD)	2011-09-22		
Name/Print	Patricia A. Verlangieri	Registration Number	42,201		

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5.1.S.C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 11, 4, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by whiter a published application, an application open to public inscredience or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.